Unknown

Dataset Information

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.


ABSTRACT:

Unlabelled

Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functional analysis of an outlier curative response of a patient with metastatic small-cell cancer to combined checkpoint kinase 1 (CHK1) inhibition and DNA-damaging chemotherapy. Whole-genome sequencing revealed a clonal hemizygous mutation in the Mre11 complex gene RAD50 that attenuated ATM signaling which in the context of CHK1 inhibition contributed, via synthetic lethality, to extreme sensitivity to irinotecan. As Mre11 mutations occur in a diversity of human tumors, the results suggest a tumor-specific combination therapy strategy in wh

SUBMITTER: Al-Ahmadie H 

PROVIDER: S-EPMC4155059 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature